

TDMS No. 97008 - 06

Test Type: CHRONIC

Route: RESPIRATORY EXPOSURE WHOLE BODY

Species/Strain: MICE/B6C3F1

P05: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)
PROPARGYL ALCOHOL

CAS Number: 107-19-7

Date Report Reqsted: 07/11/2006

Time Report Reqsted: 13:00:41

First Dose M/F: 09/17/01 / 09/17/01

Lab: BNW

F1_M3

C Number: C97008

Lock Date: 08/16/2004

Cage Range: ALL

Date Range: ALL

Reasons For Removal: ALL

Removal Date Range: ALL

Treatment Groups: Include ALL

Test Type: CHRONIC

Time Report Requested: 13:00:41

Route: RESPIRATORY EXPOSURE WHOLE BODY

CAS Number: 107-19-7

First Dose M/F: 09/17/01 / 09/17/01

Species/Strain: MICE/B6C3F1

Lab: BNW

B6C3F1 MICE MALE	CONTROL	8 PPM	16 PPM	32 PPM
Disposition Summary				
Animals Initially in Study	50	50	50	50
Early Deaths				
Accidently Killed		1		
Moribund Sacrifice	9	6	6	7
Natural Death	4		4	1
Survivors				
Natural Death		1		
Terminal Sacrifice	37	42	40	42
Animals Examined Microscopically	50	50	50	50
ALIMENTARY SYSTEM				
Gallbladder	(40)	(41)	(40)	(44)
Intestine Large, Cecum	(49)	(50)	(48)	(50)
Hemangioma				1 (2%)
Intestine Small, Ileum	(48)	(50)	(46)	(49)
Intestine Small, Jejunum	(48)	(50)	(46)	(49)
Adenoma			1 (2%)	
Carcinoma	1 (2%)	2 (4%)	1 (2%)	1 (2%)
Liver	(49)	(50)	(49)	(50)
Hemangioma			1 (2%)	
Hemangiosarcoma	1 (2%)	1 (2%)	3 (6%)	
Hepatoblastoma			1 (2%)	
Hepatocellular Adenoma	10 (20%)	14 (28%)	8 (16%)	14 (28%)
Hepatocellular Adenoma, Multiple	11 (22%)	10 (20%)	8 (16%)	1 (2%)
Hepatocellular Carcinoma	9 (18%)	8 (16%)	6 (12%)	5 (10%)
Hepatocellular Carcinoma, Multiple	1 (2%)	1 (2%)	2 (4%)	2 (4%)
Hepatocholangiocarcinoma			1 (2%)	
Mesentery	(3)	(3)	(2)	(4)
Pancreas	(49)	(50)	(49)	(50)
Sarcoma, Metastatic, Uncertain Primary Site	1 (2%)			
Salivary Glands	(50)	(50)	(50)	(50)
Stomach, Forestomach	(50)	(50)	(49)	(50)
Mast Cell Tumor Malignant, Metastatic, Uncertain Primary Site		1 (2%)		
Sarcoma		1 (2%)		

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

Time Report Requested: 13:00:41

Route: RESPIRATORY EXPOSURE WHOLE BODY

CAS Number: 107-19-7

First Dose M/F: 09/17/01 / 09/17/01

Species/Strain: MICE/B6C3F1

Lab: BNW

B6C3F1 MICE MALE	CONTROL	8 PPM	16 PPM	32 PPM
Squamous Cell Papilloma Stomach, Glandular Sarcoma	(49)	(50) 1 (2%)	1 (2%) (49)	(50)
Sarcoma, Metastatic, Uncertain Primary Site Tooth	1 (2%) (3)	(4)	(5)	(2)
CARDIOVASCULAR SYSTEM				
Heart Sarcoma, Metastatic, Uncertain Primary Site	(50) 1 (2%)	(50)	(50)	(50)
ENDOCRINE SYSTEM				
Adrenal Cortex Sarcoma, Metastatic, Uncertain Primary Site Capsule, Adenoma Subcapsular, Adenoma	(49) 1 (2%) 1 (2%)	(50)	(49)	(50)
Adrenal Medulla Pheochromocytoma Malignant	(47)	3 (6%) (50) 1 (2%)	(49)	1 (2%) (50)
Islets, Pancreatic Adenoma	(49) 1 (2%)	(50)	(49)	(50)
Pituitary Gland Thyroid Gland C-cell, Carcinoma Follicular Cell, Adenoma	(47) (49)	(50) (50) 1 (2%)	(50) (50)	(49) (50)
GENERAL BODY SYSTEM				
Peritoneum Sarcoma, Metastatic, Uncertain Primary Site	(1) 1 (100%)	(0)	(0)	(0)
GENITAL SYSTEM				
Epididymis Preputial Gland Hemangioma Prostate Seminal Vesicle	(50) (50)	(50) (50) 1 (2%) (50) (50)	(50) (50)	(50) (50) (49) (50)

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

Time Report Requested: 13:00:41

Route: RESPIRATORY EXPOSURE WHOLE BODY

CAS Number: 107-19-7

First Dose M/F: 09/17/01 / 09/17/01

Species/Strain: MICE/B6C3F1

Lab: BNW

B6C3F1 MICE MALE	CONTROL	8 PPM	16 PPM	32 PPM
Sarcoma, Metastatic, Uncertain Primary Site	1 (2%)			
Testes	(50)	(50)	(50)	(50)
Interstitial Cell, Adenoma		1 (2%)		
HEMATOPOIETIC SYSTEM				
Bone Marrow	(50)	(50)	(50)	(50)
Mast Cell Tumor Malignant, Metastatic, Uncertain Primary Site		1 (2%)		
Lymph Node	(1)	(1)	(0)	(0)
Lymph Node, Bronchial	(37)	(35)	(30)	(33)
Hemangiosarcoma				1 (3%)
Sarcoma, Metastatic, Uncertain Primary Site	1 (3%)			
Lymph Node, Mandibular	(32)	(33)	(25)	(30)
Carcinoma, Metastatic, Harderian Gland	1 (3%)			
Mast Cell Tumor Malignant, Metastatic, Uncertain Primary Site		1 (3%)		
Lymph Node, Mediastinal	(39)	(33)	(38)	(36)
Lymph Node, Mesenteric	(49)	(50)	(48)	(49)
Sarcoma, Metastatic, Uncertain Primary Site	1 (2%)			
Spleen	(49)	(50)	(49)	(50)
Hemangiosarcoma	1 (2%)		1 (2%)	
Thymus	(47)	(49)	(42)	(49)
INTEGUMENTARY SYSTEM				
Skin	(50)	(50)	(50)	(50)
Sebaceous Gland, Adenoma				1 (2%)
Subcutaneous Tissue, Fibrous Histiocytoma				2 (4%)
Subcutaneous Tissue, Hemangioma				1 (2%)
Subcutaneous Tissue, Hemangiosarcoma			1 (2%)	
MUSCULOSKELETAL SYSTEM				
Bone	(50)	(50)	(50)	(50)
Osteosarcoma	1 (2%)			1 (2%)
Sarcoma				1 (2%)
Skeletal Muscle	(1)	(1)	(0)	(0)
Sarcoma, Metastatic, Uncertain Primary Site	1 (100%)			

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

Time Report Requested: 13:00:41

Route: RESPIRATORY EXPOSURE WHOLE BODY

CAS Number: 107-19-7

First Dose M/F: 09/17/01 / 09/17/01

Species/Strain: MICE/B6C3F1

Lab: BNW

B6C3F1 MICE MALE	CONTROL	8 PPM	16 PPM	32 PPM
NERVOUS SYSTEM				
Brain	(50)	(50)	(50)	(50)
Carcinoma, Metastatic, Harderian Gland	1 (2%)			
Sarcoma, Metastatic, Bone				1 (2%)
RESPIRATORY SYSTEM				
Lung	(50)	(50)	(50)	(50)
Alveolar/Bronchiolar Adenoma	9 (18%)	5 (10%)	8 (16%)	6 (12%)
Alveolar/Bronchiolar Adenoma, Multiple	1 (2%)		1 (2%)	1 (2%)
Alveolar/Bronchiolar Carcinoma	7 (14%)	6 (12%)	6 (12%)	7 (14%)
Alveolar/Bronchiolar Carcinoma, Multiple		1 (2%)	1 (2%)	
Carcinoma, Metastatic, Harderian Gland	2 (4%)		1 (2%)	
Hepatoblastoma, Metastatic, Liver			1 (2%)	
Hepatocellular Carcinoma, Metastatic, Liver	3 (6%)	2 (4%)	5 (10%)	2 (4%)
Bronchiole, Adenoma	1 (2%)			
Nose	(49)	(50)	(50)	(50)
Hemangioma		1 (2%)		
Olfactory Epithelium, Sarcoma, Metastatic, Bone				1 (2%)
Respiratory Epithelium, Adenoma		1 (2%)	4 (8%)	7 (14%)
SPECIAL SENSES SYSTEM				
Eye	(49)	(50)	(48)	(49)
Melanoma Malignant		1 (2%)		
Harderian Gland	(49)	(50)	(49)	(50)
Adenoma	3 (6%)	10 (20%)	6 (12%)	9 (18%)
Carcinoma	3 (6%)	3 (6%)	5 (10%)	1 (2%)
Bilateral, Adenoma				2 (4%)
URINARY SYSTEM				
Kidney	(49)	(50)	(50)	(50)
Mast Cell Tumor Malignant, Metastatic, Uncertain Primary Site				1 (2%)

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

Route: RESPIRATORY EXPOSURE WHOLE BODY

Species/Strain: MICE/B6C3F1

B6C3F1 MICE MALE	CONTROL	8 PPM	16 PPM	32 PPM
Sarcoma, Metastatic, Uncertain Primary Site	1 (2%)		1 (2%)	1 (2%)
Renal Tubule, Adenoma			(49)	(50)
Urinary Bladder	(49)	(50)	1 (2%)	
Transitional Epithelium, Papilloma				
SYSTEMIC LESIONS				
Multiple Organs	*(50)	*(50)	*(50)	*(50)
Histiocytic Sarcoma	1 (2%)	1 (2%)		1 (2%)
Lymphoma Malignant	1 (2%)	2 (4%)	1 (2%)	2 (4%)

a - Number of animals examined microscopically at site and number of animals with lesion

* Number of animals with any tissue examined microscopically

Test Type: CHRONIC

Route: RESPIRATORY EXPOSURE WHOLE BODY

Species/Strain: MICE/B6C3F1

B6C3F1 MICE MALE	CONTROL	8 PPM	16 PPM	32 PPM
Tumor Summary for Males				
Total Animals with Primary Neoplasms (b)	38	42	40	40
Total Primary Neoplasms	63	76	70	69
Total Animals with Benign Neoplasms	28	30	28	33
Total Benign Neoplasms	37	46	41	45
Total Animals with Malignant Neoplasms	22	24	26	21
Total Malignant Neoplasms	26	30	29	24
Total Animals with Metastatic Neoplasms	6	3	7	4
Total Metastatic Neoplasms	17	5	7	5
Total Animals with Malignant Neoplasms Uncertain Primary Site	1	1		1
Total Animals with Neoplasms Uncertain-Benign or Malignant				
Total Uncertain Neoplasms				

*** END OF MALE ***

a - Number of animals examined microscopically at site and number of animals with lesion
 b - Primary tumors: all tumors except metastatic tumors

Test Type: CHRONIC

Time Report Requested: 13:00:41

Route: RESPIRATORY EXPOSURE WHOLE BODY

CAS Number: 107-19-7

First Dose M/F: 09/17/01 / 09/17/01

Species/Strain: MICE/B6C3F1

Lab: BNW

B6C3F1 MICE FEMALE	CONTROL	8 PPM	16 PPM	32 PPM
Disposition Summary				
Animals Initially in Study	50	50	50	50
Early Deaths				
Moribund Sacrifice	9	8	15	10
Natural Death	2	3	3	2
Survivors				
Terminal Sacrifice	39	39	32	38
Animals Examined Microscopically	50	50	50	50
ALIMENTARY SYSTEM				
Esophagus	(50)	(50)	(50)	(50)
Gallbladder	(41)	(40)	(45)	(44)
Intestine Large, Cecum	(48)	(48)	(47)	(49)
Intestine Large, Rectum	(49)	(48)	(48)	(49)
Intestine Small, Duodenum	(49)	(47)	(48)	(48)
Carcinoma			1 (2%)	
Intestine Small, Ileum	(48)	(47)	(47)	(49)
Intestine Small, Jejunum	(48)	(47)	(47)	(48)
Carcinoma		1 (2%)		
Liver	(50)	(50)	(50)	(50)
Carcinoma, Metastatic, Islets, Pancreatic	1 (2%)			
Hemangioma		1 (2%)		
Hemangiosarcoma				1 (2%)
Hepatocellular Adenoma	12 (24%)	7 (14%)	9 (18%)	4 (8%)
Hepatocellular Adenoma, Multiple	3 (6%)	7 (14%)	3 (6%)	
Hepatocellular Carcinoma	4 (8%)	6 (12%)		
Hepatocholangiocarcinoma			1 (2%)	
Osteosarcoma, Metastatic, Bone				1 (2%)
Mesentery	(9)	(13)	(7)	(5)
Hepatocholangiocarcinoma, Metastatic, Liver			1 (14%)	
Osteosarcoma, Metastatic, Bone				1 (20%)
Pancreas	(50)	(48)	(50)	(49)
Hepatocholangiocarcinoma, Metastatic, Liver			1 (2%)	
Sarcoma, Metastatic, Skin				1 (2%)
Salivary Glands	(50)	(50)	(50)	(50)
Stomach, Forestomach	(50)	(50)	(50)	(50)

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

Time Report Requested: 13:00:41

Route: RESPIRATORY EXPOSURE WHOLE BODY

CAS Number: 107-19-7

First Dose M/F: 09/17/01 / 09/17/01

Species/Strain: MICE/B6C3F1

Lab: BNW

B6C3F1 MICE FEMALE	CONTROL	8 PPM	16 PPM	32 PPM
Squamous Cell Papilloma Stomach, Glandular Tongue	1 (2%) (50) (1)	(48) (1)	(48) (0)	(49) (0)
Squamous Cell Carcinoma Squamous Cell Papilloma Tooth	1 (100%) (0)	1 (100%) (0)	(1)	(0)
CARDIOVASCULAR SYSTEM				
Blood Vessel Aorta, Sarcoma, Metastatic, Skin Heart Hemangiosarcoma Sarcoma, Metastatic, Skin	(1) 1 (100%) (50) 1 (2%)	(0) (50)	(0) (50) 1 (2%)	(0) (50) 1 (2%)
ENDOCRINE SYSTEM				
Adrenal Cortex Hemangiosarcoma Capsule, Adenoma Capsule, Carcinoma Adrenal Medulla Pheochromocytoma Benign Pheochromocytoma Malignant Islets, Pancreatic Carcinoma Pituitary Gland Pars Distalis, Adenoma Pars Distalis, Carcinoma Pars Intermedia, Adenoma Thyroid Gland Follicular Cell, Adenoma	(49) (48) 1 (2%) (50) 1 (2%) (50) 4 (8%) 1 (2%) (50) 2 (4%)	(50) 1 (2%) (46) 2 (4%) (48) (49) 7 (14%) (50) 3 (6%)	(50) 1 (2%) (50) 1 (2%) (50) 7 (15%) (50) 1 (2%)	(50) 1 (2%) (50) 1 (2%) (50)
GENERAL BODY SYSTEM				
Tissue NOS Carcinoma	(1) 1 (100%)	(0)	(0)	(0)

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

Time Report Requested: 13:00:41

Route: RESPIRATORY EXPOSURE WHOLE BODY

CAS Number: 107-19-7

First Dose M/F: 09/17/01 / 09/17/01

Species/Strain: MICE/B6C3F1

Lab: BNW

B6C3F1 MICE FEMALE	CONTROL	8 PPM	16 PPM	32 PPM
GENITAL SYSTEM				
Ovary	(49)	(50)	(49)	(49)
Cystadenoma	6 (12%)	3 (6%)		
Granulosa Cell Tumor Benign		1 (2%)	1 (2%)	
Hemangiosarcoma			1 (2%)	
Leiomyosarcoma	1 (2%)			
Luteoma		2 (4%)		
Osteosarcoma, Metastatic, Bone				1 (2%)
Tubulostromal Adenoma		1 (2%)		1 (2%)
Uterus	(50)	(50)	(50)	(49)
Carcinoma			1 (2%)	
Hemangiosarcoma			4 (8%)	
Leiomyosarcoma	1 (2%)			
Polyp Stromal	2 (4%)	1 (2%)	3 (6%)	2 (4%)
Sarcoma Stromal				1 (2%)
HEMATOPOIETIC SYSTEM				
Bone Marrow	(50)	(49)	(50)	(50)
Hemangiosarcoma	2 (4%)			
Lymph Node	(9)	(4)	(5)	(4)
Sarcoma, Metastatic, Skin			1 (20%)	
Lumbar, Hemangiosarcoma		1 (25%)		
Lymph Node, Bronchial	(42)	(40)	(38)	(32)
Hepatocellular Carcinoma, Metastatic, Liver	1 (2%)			
Hepatocholangiocarcinoma, Metastatic, Liver			1 (3%)	
Lymph Node, Mandibular	(38)	(33)	(38)	(39)
Lymph Node, Mediastinal	(45)	(38)	(42)	(33)
Hepatocholangiocarcinoma, Metastatic, Liver			1 (2%)	
Sarcoma, Metastatic, Skin	1 (2%)		1 (2%)	
Lymph Node, Mesenteric	(48)	(47)	(49)	(49)
Sarcoma, Metastatic, Skin			1 (2%)	
Spleen	(50)	(48)	(50)	(50)
Hemangiosarcoma	1 (2%)	1 (2%)	1 (2%)	1 (2%)
Osteosarcoma, Metastatic, Bone				1 (2%)
Thymus	(49)	(47)	(48)	(50)
Alveolar/Bronchiolar Carcinoma, Metastatic, Lung			1 (2%)	
Sarcoma, Metastatic, Skin	1 (2%)			

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

Time Report Requested: 13:00:41

Route: RESPIRATORY EXPOSURE WHOLE BODY

CAS Number: 107-19-7

First Dose M/F: 09/17/01 / 09/17/01

Species/Strain: MICE/B6C3F1

Lab: BNW

B6C3F1 MICE FEMALE	CONTROL	8 PPM	16 PPM	32 PPM
INTEGUMENTARY SYSTEM				
Mammary Gland	(50)	(50)	(50)	(48)
Carcinoma				2 (4%)
Fibroadenoma			1 (2%)	
Skin	(50)	(50)	(50)	(50)
Subcutaneous Tissue, Fibrous Histiocytoma, Multiple		1 (2%)		
Subcutaneous Tissue, Liposarcoma		1 (2%)		
Subcutaneous Tissue, Sarcoma	2 (4%)		2 (4%)	2 (4%)
MUSCULOSKELETAL SYSTEM				
Bone	(50)	(50)	(50)	(50)
Osteosarcoma				1 (2%)
Sarcoma		1 (2%)		
Skeletal Muscle	(1)	(1)	(2)	(0)
Hemangiosarcoma		1 (100%)		
Hepatoblastoma, Metastatic, Liver			1 (50%)	
Sarcoma, Metastatic, Skin	1 (100%)			
NERVOUS SYSTEM				
Brain	(50)	(50)	(50)	(50)
Carcinoma, Metastatic, Pituitary Gland	1 (2%)			
Spinal Cord	(0)	(0)	(0)	(1)
Osteosarcoma, Metastatic, Bone				1 (100%)
RESPIRATORY SYSTEM				
Larynx	(50)	(50)	(50)	(50)
Lung	(50)	(50)	(50)	(50)
Alveolar/Bronchiolar Adenoma	3 (6%)	6 (12%)	2 (4%)	3 (6%)
Alveolar/Bronchiolar Carcinoma	2 (4%)	3 (6%)		1 (2%)
Alveolar/Bronchiolar Carcinoma, Multiple			2 (4%)	1 (2%)
Carcinoma, Metastatic, Harderian Gland				1 (2%)
Hemangiosarcoma, Metastatic, Uterus			1 (2%)	

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

Time Report Requested: 13:00:41

Route: RESPIRATORY EXPOSURE WHOLE BODY

CAS Number: 107-19-7

First Dose M/F: 09/17/01 / 09/17/01

Species/Strain: MICE/B6C3F1

Lab: BNW

B6C3F1 MICE FEMALE	CONTROL	8 PPM	16 PPM	32 PPM
Hepatocellular Carcinoma, Metastatic, Liver	3 (6%)	1 (2%)		
Hepatocholangiocarcinoma, Metastatic, Liver			1 (2%)	
Liposarcoma, Metastatic, Skin		1 (2%)		
Osteosarcoma, Metastatic, Bone				1 (2%)
Sarcoma, Metastatic, Skin	1 (2%)			
Nose	(50)	(50)	(50)	(50)
Respiratory Epithelium, Adenoma		2 (4%)	4 (8%)	6 (12%)
Pleura	(1)	(0)	(0)	(0)
Alveolar/Bronchiolar Carcinoma, Metastatic, Lung	1 (100%)			
SPECIAL SENSES SYSTEM				
Eye	(49)	(48)	(49)	(48)
Melanoma Benign		1 (2%)		
Harderian Gland	(50)	(49)	(50)	(50)
Adenoma	4 (8%)	2 (4%)	5 (10%)	3 (6%)
Carcinoma		1 (2%)	1 (2%)	2 (4%)
URINARY SYSTEM				
Kidney	(50)	(50)	(50)	(50)
Osteosarcoma, Metastatic, Bone				1 (2%)
Transitional Epithelium, Carcinoma				1 (2%)
Urinary Bladder	(50)	(47)	(48)	(49)
SYSTEMIC LESIONS				
Multiple Organs	*(50)	*(50)	*(50)	*(50)
Histiocytic Sarcoma	1 (2%)	3 (6%)	2 (4%)	2 (4%)
Lymphoma Malignant	13 (26%)	8 (16%)	7 (14%)	6 (12%)

a - Number of animals examined microscopically at site and number of animals with lesion

* Number of animals with any tissue examined microscopically

Test Type: CHRONIC

Route: RESPIRATORY EXPOSURE WHOLE BODY

Species/Strain: MICE/B6C3F1

B6C3F1 MICE FEMALE	CONTROL	8 PPM	16 PPM	32 PPM
Tumor Summary for Females				
Total Animals with Primary Neoplasms (b)	37	42	42	34
Total Primary Neoplasms	69	76	62	50
Total Animals with Benign Neoplasms	26	31	32	20
Total Benign Neoplasms	39	47	37	26
Total Animals with Malignant Neoplasms	23	24	23	19
Total Malignant Neoplasms	30	29	25	24
Total Animals with Metastatic Neoplasms	7	2	4	3
Total Metastatic Neoplasms	13	2	11	9
Total Animals with Malignant Neoplasms Uncertain Primary Site				
Total Animals with Neoplasms Uncertain-Benign or Malignant Total Uncertain Neoplasms				

*** END OF REPORT ***

a - Number of animals examined microscopically at site and number of animals with lesion
 b - Primary tumors: all tumors except metastatic tumors